




## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> :  C07D 471/04		A1	(11) International Publication Number: <b>WO 97/03074</b>
			(43) International Publication Date: 30 January 1997 (30.01.97)
(21) International Application Number: PCT/KR96/00080			Jang, Hoon [KR/KR]; 1664-16, Shilim-8-dong, Kwanak-ku, Seoul 151-018 (KR). SOHN, Sang, Kwon [KR/KR]; 410-1, Rulgeon-dong, Jangan-ku, Suwon-city, Kyunggi-do 440-320 (KR). KANG, Bog, Goo [KR/KR]; 37-35, Younghwa-dong, Jangan-ku, Suwon-city, Kyunggi-do 440-050 (KR). KIM, Young, Heui [KR/KR]; 451, Sekyo-dong, Pyungtack-city, Kyunggi-do 450-100 (KR). SEO, Kwi, Hyon [KR/KR]; 392-27, Songjuk-dong, Jangan-ku, Suwon-city, Kyunggi-do 440-210 (KR).
(22) International Filing Date: 1 June 1996 (01.06.96)			
(30) Priority Data: 1995/20514 12 July 1995 (12.07.95) KR			
(71) Applicant (for all designated States except US): YUNGJIN PHARMACEUTICAL CO., LTD. [KR/KR]; 277-58, Sungsu-dong 2-ka, Sungdong-ku, Seoul 133-111 (KR).			
(72) Inventors; and			
(75) Inventors/Applicants (for US only): YOO, Han, Yong [KR/KR]; 208-701, Family Apartment, 150, Moonjung-dong, Songpa-ku, Seoul 138-200 (KR). CHUNG, Kae, Jong [KR/KR]; 107-1404, Hanbo Mido Apartment, Daechi-dong, Kangnam-ku, Seoul 135-280 (KR). CHANG, Man, Sik [KR/KR]; 1303-205, Mokdong Apartment, Sinjung-dong, Yangchun-ku, Seoul 158-070 (KR). KIM, Sung, Gyu [KR/KR]; 149-6, Sunhwa-3-dong, Jung-ku, Taejeon 301-053 (KR). CHOI, Wahn, Soo [KR/KR]; 144-7, Sadang-2-dong, Kongjak-ku, Seoul 152-090 (KR). KANG, Dae, Pil [KR/KR]; 531-3, Seojeong-dong, Pyungtack-city, Kyunggi-do 459-010 (KR). KIM, Young, Hun [KR/KR]; B01, Wooseong Art Villa, 869-6, Seojeong-dong, Pyungtack-city, Kyunggi-do 459-010 (KR). PAEK,			
(81) Designated States: CA, CN, JP, US, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).			

## Published

With international search report.

## (54) Title: 4-AMINO-3-ACYLNAPHTHYRIDINE DERIVATIVES



## (57) Abstract

A novel 4-amino-3-acylnaphthyridine derivatives represented by general formula (I), wherein R<sub>1</sub> is hydrogen atom, a C<sub>1</sub>-C<sub>6</sub> lower alkyl group, a C<sub>1</sub>-C<sub>6</sub> lower alkoxy group, a C<sub>1</sub>-C<sub>6</sub> lower alkoxyalkyl group, a C<sub>3</sub>-C<sub>6</sub> cycloalkyl group, a C<sub>3</sub>-C<sub>6</sub> cycloalkyl C<sub>1</sub>-C<sub>6</sub> alkyl group, a substituted or unsubstituted phenyl, or a phenyl C<sub>1</sub>-C<sub>6</sub> alkyl group of which phenyl group may be substituted; R<sub>2</sub> is hydrogen atom, a C<sub>1</sub>-C<sub>6</sub> lower alkyl group, a C<sub>1</sub>-C<sub>6</sub> alkoxy group, a C<sub>1</sub>-C<sub>6</sub> alkylthio group, or a group of a formula: NR<sub>6</sub>R<sub>7</sub> wherein R<sub>6</sub> and R<sub>7</sub>, identical to or different from each other, are independently hydrogen atom or a C<sub>1</sub>-C<sub>6</sub> lower alkyl group, or R<sub>6</sub> and R<sub>7</sub> may form together 5-membered or 6-membered cycloalkyl group; R<sub>3</sub> is hydrogen atom, a C<sub>1</sub>-C<sub>6</sub> lower alkyl group, a C<sub>1</sub>-C<sub>6</sub> alkoxy group, a C<sub>1</sub>-C<sub>6</sub> alkylthio group, an amino group substituted with one or two C<sub>1</sub>-C<sub>6</sub> alkyl groups, a halogen atom, a cyano group, a C<sub>1</sub>-C<sub>6</sub> alkanoyl group, or trifluoromethyl group; R<sub>4</sub> is hydrogen atom or a substituted or unsubstituted C<sub>1</sub>-C<sub>6</sub> alkyl group; R<sub>5</sub> is hydrogen atom, a C<sub>1</sub>-C<sub>6</sub> lower alkyl group, a C<sub>1</sub>-C<sub>6</sub> alkoxy group, an amino group substituted with one or two C<sub>1</sub>-C<sub>6</sub> alkyl groups, a C<sub>1</sub>-C<sub>6</sub> alkylthio group, a halogen atom, a cyano group, a hydroxycarbamoyl group, a carboxy group, a C<sub>1</sub>-C<sub>6</sub> alkanoyl group, or trifluoromethyl group, or an alkyl group which forms together with R<sub>4</sub> a 5-membered or 6-membered cycloalkyl group; m is an integer from 0 to 4, inclusive; and n is an integer from 1 to 3, inclusive; with proviso that all alkyl and alkoxy groups may be linear or branched, and said halogen atom means fluorine, chlorine or bromine atom, or its pharmaceutically acceptable salts are disclosed. These compounds show excellent anti-ulcer activity.

***FOR THE PURPOSES OF INFORMATION ONLY***

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MN	Mauritania	UZ	Uzbekistan
GA	Gabon	MN	Mauritania	VN	Viet Nam

## 4-AMINO-3-ACYLNAPHTHYRIDINE DERIVATIVES

### FIELD OF THE INVENTION

5 The Present invention is related to new 4-amino-3-acylnaphthyridine derivatives or their pharmaceutically acceptable salts, which are useful as anti-ulcer or gastric juice-secretion suppressor, to a method for producing them and intermediates for the method.

10

### BACKGROUND OF THE INVENTION


It has been reported that the gastrointestinal ulcers 15 may be caused by a excessive secretion of acids such as hydrochloric acid or pepsin as well as by an action of anti-inflammatory agents such as indomethacin, toxic chemicals, pathogenic virus or toxic microorganisms. In particular, it had been reported that  $H^+/K^+$  ATPase, a proton 20 carrying enzyme which occurs in gastric mucosa, is involved in the formation of ulcer caused by a secretion of excess gastric juices.

EP 339768A, EP 0334491A and USP 4343804 disclose 4-aminoquinoline derivatives having an effective 25 anti-gastric juice secretion activity.

The present inventors surprisingly found out that if quinoline nucleus of 4-aminoquinoline derivatives of the prior arts is replaced with naphthyridine parent-nucleus, the resulting new compounds showed potent anti-ulcer, anti-gastric 30 juice secretion and anti- $H^+/K^+$  ATPase activities.

SUMMARY OF THE INVENTION

Therefore, an object of the present invention is to provide new 4-amino-3-acylnaphthyridine derivatives 5 represented by the following general formula (I):



wherein

15 R<sub>1</sub> is hydrogen atom, a C<sub>1</sub> - C<sub>6</sub> lower alkyl group, a C<sub>1</sub> - C<sub>6</sub> lower alkoxy group, C<sub>1</sub> - C<sub>6</sub> lower alkoxyalkyl group, a C<sub>3</sub> - C<sub>6</sub> cycloalkyl group, a C<sub>3</sub> - C<sub>6</sub> cycloalkyl C<sub>1</sub> - C<sub>6</sub> alkyl group, a substituted or unsubstituted phenyl, or a phenyl C<sub>1</sub> - C<sub>6</sub> alkyl group of which phenyl group may be substituted;

20 R<sub>2</sub> is hydrogen atom, a C<sub>1</sub> - C<sub>6</sub> lower alkyl group, a C<sub>1</sub> - C<sub>6</sub> alkoxy group, a C<sub>1</sub> - C<sub>6</sub> alkylthio group, or a group of a formula : NR<sub>6</sub>R<sub>7</sub> wherein R<sub>6</sub> and R<sub>7</sub>, identical to or different from each other, are independently hydrogen atom or a C<sub>1</sub> - C<sub>6</sub> lower alkyl group, or R<sub>6</sub> and R<sub>7</sub> may form together 25 5-membered or 6-membered cycloalkyl group;

30 R<sub>3</sub> is hydrogen atom, a C<sub>1</sub> - C<sub>6</sub> lower alkyl group, a C<sub>1</sub> - C<sub>6</sub> alkoxy group, a C<sub>1</sub> - C<sub>6</sub> alkylthio group, an amino group substituted with one or two C<sub>1</sub> - C<sub>6</sub> alkyl groups, a halogen atom, a cyano group, a C<sub>1</sub> - C<sub>6</sub> alkanoyl group, or trifluoromethyl group;

R<sub>4</sub> is hydrogen atom or a substituted or unsubstituted C<sub>1</sub> - C<sub>6</sub> alkyl group;

R<sub>5</sub> is hydrogen atom, a C<sub>1</sub> - C<sub>6</sub> lower alkyl group, a C<sub>1</sub> - C<sub>6</sub> alkoxy group, an amino group substituted with one or two

5 C<sub>1</sub> - C<sub>6</sub> alkyl groups, a C<sub>1</sub> - C<sub>6</sub> alkylthio group, a halogen atom, a cyano group, a hydroxycarbamoyl group, a carboxy group, a C<sub>1</sub> - C<sub>6</sub> alkanoyl group, or trifluoromethyl group, or an alkyl group which forms together with R<sub>4</sub> a 5-membered or 6-membered cycloalkyl group;

10 m is an integer from 0 to 4, inclusive; and

n is an integer from 1 to 3, inclusive;

with proviso that all alkyl and alkoxy groups may be linear or branched, and said halogen atom means fluorine, chlorine or bromine atom,

15 or their pharmaceutically acceptable salts.

For the present invention, if a carbon atom to which R<sub>4</sub> other than hydrogen atom is bonded is asymmetric, the compounds (I) may have optically active isomers such as enantiomers, racemic mixtures, or mixtures thereof, all of 20 them are embraced within scope of the present invention,

According to the present invention, a method for producing the compounds is also provided.


The above and other objects and features of the present invention will be apparent to the skilled in the art from the 25 following detailed description.

DETAILED DESCRIPTION OF THE INVENTION

The pharmaceutically acceptable salts of the compound (I) of the present invention include acid-addition salts of 5 the compound (I) with pharmaceutically acceptable organic and inorganic acids, for example hydrochloric, sulfuric, phosphoric, citric, formic, acetic, fumaric, maleic, malonic, tartaric, methanesulfonic, or p-toluene sulfonic acid.


The compound represented by the general formula (I) may 10 be prepared by reacting the compound represented by the general formula (II)

15



wherein, R<sub>1</sub>, R<sub>2</sub>, and R<sub>3</sub> have the same meanings as defined above; and X is a leaving group which may be substituted with an amine 20 group, and may be exemplified by a halogen atom, OS(O)<sub>2</sub>R<sub>8</sub> or OP(O)(OR<sub>9</sub>)<sub>2</sub> in which R<sub>8</sub> is methyl, ethyl, trifluoromethyl, phenyl, or p-toluenyl group, and R<sub>9</sub> is methyl, ethyl, propyl, or phenyl group which may be substituted, with the compound represented by the general formula (III):

25



30


wherein,  $R_4$ ,  $R_6$ ,  $m$  and  $n$  have the same meanings as defined above.


The reaction of the compound (II) with the compound (III) can be carried out in a solvent, for example, not limited thereto, dichloromethane, chloroform, tetrahydrofuran, dioxan, anisole, acetonitrile, propionitrile, or dimethylformamide, dimethylsulfoxide at the temperature in the range of room temperature to boiling point of the solvent employed. The compound (III) may be used in an amount of equivalent to the compound (II) or more.

10 A base may be added to facilitate the reaction. The base, which may be employed for this purpose, may include, not limited thereto, an inorganic base such as sodium carbonate, potassium carbonate, or sodium bicarbonate, or an organic base such as triethylamine, diisopropylethylamine, dimethylaniline, pyridine, or quinoline. If no base is added to the reaction system, the compound (III) is 15 preferably used in an amount of more than 2 equivalents.

The compound (II) of the present invention can be 20 prepared by following the reactions shown in the following Reaction Scheme 1.

[Reaction Scheme 1]





wherein, R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, and X have the same meanings as defined  
15 above.

The compound (IV) is reacted with the compound (V) in absence of solvent at a temperature of 100°C to 150°C, or in the presence of solvent selected from toluen, chlorobenzene or xylene at a temperature of the boiling point of the solvent  
20 employed to give the compound (VI). The compound (VI) is then subjected to cyclization in diphenyl ether by heating to a temperature of 200°C to the boiling point of the solvent employed to prepare the naphthylidine nucleus of the formula (VII). The compound (II) in which the group X is a halogen  
25 atom, preferably chlorine, can be prepared by reacting the compound (VII) with phosphoryl chloride, phosphorous trichloride, or phosphorous pentachloride under the reaction conditions known to those of skill in the art. The compound (II) in which the group X is sulfonate or phosphonate group can  
30 be prepared by reacting the compound (VII) with sulfonyl

chloride or phosphoryl chloride in dichloromethane, chloroform, or 1,2-dichloroethane in the presence of a base such as triethylamine, diisopropylethylamine, dimethylaniline, pyridine or quinoline at a temperature of -10°C to room 5 temperature to give the compound (II).

The novel 4-amino-3-acylnaphthyridine derivatives represented by the general formula (I) or their pharmaceutically acceptable salts effectively inhibit H<sup>+</sup>/K<sup>+</sup> ATPase, a proton carrying enzyme, so that they can 10 advantageously used for inhibiting the secretion of gastric juices or treating gastrointestinal ulcers.

The methods and results of pharmacological experiments and acute toxicity experiments carried out using the 15 representative compounds (I) of the present invention are described below.

### 1. Inhibition of H<sup>+</sup>/K<sup>+</sup> ATPase

Inhibition of H<sup>+</sup>/K<sup>+</sup> ATPase, a proton carrying enzyme, was measured by following the procedure of Saccomani *et al.* 20 [Biochim. Biophys. Acta., 465, 311-330 (1977)]. Thus, a homogenate of the gastric mucose membrane of rabbit was used to prepare vesicles containing H<sup>+</sup>/K<sup>+</sup> ATPase by employing differential centrifugation and discontinuous density gradient centrifugation in Ficoll. The vesicles containing the enzyme 25 were preincubated in a solution (0.5ml) containing  $1 \times 10^{-4}$ M,  $1 \times 10^{-5}$ M,  $1 \times 10^{-6}$ M, or  $1 \times 10^{-7}$ M of the inventive compounds shown in Table 1 and 5 mM of imidazole buffer (pH 7.4) at a temperature of about 37°C for about 30 minutes. omeprazole was used as a control. A solution containing 2 mM of 30 magnesium chloride, 40 mM of imidazole buffer (pH 7.4), 10 mM

of potassium chloride and 10 mM of ATP was added to the mixture. The resulting mixture was incubated at 37°C for 15 minutes and the reaction was terminated by adding 1 ml of ice-cold 22% solution of trichloroacetic acid. Enzyme activity was calculated by measuring the separated inorganic phosphate by following the method of Fiske and Subbarow [J. Biol. Chem., 66, 375-440 (1925)]. The concentrations (IC<sub>50</sub>) of the test compounds which inhibit the enzyme activity by 50% are shown in Table 1.

10

Table 1

Test Compound	H <sup>+</sup> /K <sup>+</sup> ATPase Inhibition (IC <sub>50</sub> , 10 <sup>-5</sup> M)
Example 11	3.16
Example 13	2.51
Example 21	4.57
Example 29	2.69
Example 31	1.49
Example 32	7.50
Example 34	2.34
Example 35	2.05
Example 37	2.80
Example 41	1.26
Example 42	1.47
Example 43	1.82
Example 44	1.14
Example 45	3.93
Example 55	1.68
Omeprazole	5.75 × 10 <sup>-5</sup> M

15

20

25

25

## 2. Inhibition of Gastric Secretion

Inhibition of gastric secretion was measured by following the procedure of Shay ligation (Gastroenterology,

30

1954, 26, 903). Thus, male Sprague-Dawley rats weighing 180 - 200g were starved for 24 hours and their pylorus were ligated. Then, the inventive compounds shown in Table 2 or omeprazole as a positive control was administered into duodenum. Four 5 hours later, the stomach was removed, and the acidity and amount of gastric juice were measured. By comparing the measured values with the acidity and amount of the gastric juice of the stomach of the reference group to which no test compound was administered, the inhibition of gastric secretion 10 was calculated. The effective dose ( $ED_{50}$ ) of the test compounds which inhibit the gastric secretion by 50% are shown in Table 2.

Table 2

15	Test Compound	Gastric juice Secretion Inhibition ( $ED_{50}$ , mg/kg)
	Example 13	42.1% (12.5 mg/kg)
	Example 15	30.0
	Example 21	11.7
	Example 32	36.6
20	Example 34	30.0
	Example 37	13.3
	Example 49	35.8% (12.5 mg/kg)

## 25 3. Ulcer Inhibition

## 1) Inhibition of ethanol-induced lesions

Inhibition activity of the inventive compound on the ethanol-induced lesions was measured by using male Sprague-Dawley rats weighing 180 - 200g. Thus, rats were 30 starved for 24 hours, and the inventive compounds shown in

Table 3 or omeprazole as a positive control was orally administered. Thirty minutes later, absolute ethanol (5 ml/kg) was orally administered. 1.5 hours later, the stomach was removed, and the degree of the wound of the stomach was 5 measured. By comparing the measured values with the degree of the wound of the stomach the reference group to which no test compound was administered, the concentrations ( $IC_{50}$ ) of the test compounds which inhibit the ulcer by 50% were calculated and are shown in Table 3.

10 2) **Inhibition of mepirizole-induced ulcer.**

Inhibition activity of the inventive compound on the mepirizole-induced ulcer was measured by using male Sprague-Dawley rats weighing 200 - 230g. Thus, rats were not starved, and the inventive compounds shown in Table 3 or 15 omeprazole as a positive control was orally administered. Thirty minutes later, mepirizole suspended in 1% CMC ( 250 mg/kg) was orally administered. Before administration, the rats were starved for 24 hours, the duodena were removed. The degree of the ulcer thereof was measured. By comparing 20 the measured values with the degree of the ulcer of the duodena of the reference group to which no test compound was administered, the effective doses ( $ED_{50}$ ) of the test compounds which inhibit the ulcer by 50% were calculated and are shown in Table 3.

25 3) **Inhibition of indomethacin-induced lesions**

Inhibition activities of the inventive compounds on the indomethacin-induced lesions was measured by using male Sprague-Dawley rats. Thus, rats were starved for 48 hours and prohibited from being supplied with water for 2 hours, 30 and 35 mg/kg of indomethacin (Sigma Co.) as a causative of

gastric lesions was subcutaneously administered. Before Indomethacine treatment, the inventive compounds shown in Table 3 or omeprazole as a positive control was orally administered, and the inhibitions of lesions by the action of 5 the test compounds were observed. The effective doses ( $ED_{50}$ ) of the test compounds which inhibit the lesions by 50% were measured and are shown in Table 3.

#### 4) Inhibition of stress-induced ulcer

Inhibition activity of the inventive compound on the 10 stress-induced ulcer was evaluated by using male Sprague-Dawley rats. Thus, rats were starved for 24 hours prior to carrying out the experiment.

Stress is an important factor for causing gastric ulcer, and was applied to rats by immersing them in water. 15 Then, the inventive compounds shown in Table 3 or omeprazole as a control was orally administered, and the inhibitions of ulcer by the action of the test compounds were observed. The concentrations ( $ED_{50}$ ) of the test compounds which inhibit the ulcer by 50% were measured and are shown in Table 3.

#### 20 5) Inhibition of acetic acid-induced ulcer

Inhibition activity of the inventive compound on the acetic acid-induced ulcer was evaluated by using male Sprague-Dawley rats. Thus, rats were starved for 5 hours prior to carrying out the experiment.

25 20 Microliter of 30% acetic acid was injected into the submucosal layer of the stomach using a microsyringe to induce a circular ulcer on the stomach. Various doses of the inventive compounds or omeprazole as a positive control were orally administered for 10 days, and the healing of ulcer by 30 the action of the test compounds were observed. The

percentages of the healing of the ulcer were calculated by comparing them with that of reference group.

Table 3

5

10

Test Compound	Anti-ulcer activity (ED <sub>50</sub> , mg/kg)				
	Ethanol	Mepirizole	Indomethacin	Stress	Acetic acid*
Control (Omeprazole)	17.5	2.8	1.2	4.4	27.1
Ex. 21	11.2	64.1	2.1	13.0	22.0
Ex. 15	12.8	-	2.1	-	-
Ex. 34	30.6	-	4.9	-	-

\* : Percentage of healing in 30 mg/kg

#### 4. Acute Toxicity

15 ICR mice (male and female) were orally administered with high doses (maximum dose : 5 g/kg) of inventive compound (Example 21) and were observed for their sudden death or a lasting of morbid conditions for 14 days. A median lethal dose (LD<sub>50</sub>), an index of acute toxicity was measured and is 20 shown in Table 4.

Table 4

25

30

Compound	Sexuality	Dose (mg/kg)	No. of animals	No. of Death	Lethality (%)	LD <sub>50</sub> (mg/kg)
Ex. 21	Male	0	6	0	0	2336
		40	6	0	0	
		200	6	0	0	
		1000	6	0	0	
		5000	6	6	100	
	Female	0	6	0	0	1133
		40	6	0	0	
		200	6	0	0	
		1000	6	1	17	
		5000	6	6	100	

As can be seen from the results of Tables 1 to 4, it was confirmed that 4-amino-3-acylnaphthyridine derivatives show excellent inhibition activity against H<sup>+</sup>/K<sup>+</sup> ATPase and effectively suppress the secretion of gastric juices so that 5 they can advantageously be used as an anti-ulcer agent.

The present invention will be described in more detail by way of Examples.

Example 1

10 Preparation of ethyl 4-(2-methylphenylamino)-8-methoxy-1,7-naphthyridine-3-carboxylate.

(A) Ethyl 2-ethoxycarbonyl-3-(2-methoxypyridine-3-yl)aminoacrylate

3-amino-2-methoxypyridine (12.0g) was reacted with 15 diethyl ethoxymethylene malonate (23.0g) at a temperature of 120°C to 130°C for 30 minutes while distilling ethanol produced during the reaction. After completion of the reaction, the reaction mixture was cooled to 60°C, and poured into petroleum ether (200 ml) and cooled to 0°C. The 20 resulting precipitates were filtered to give 23.5g (82%) of the titled compound.

m.p. : 65°C

<sup>1</sup>H-NMR (CDCl<sub>3</sub>) : δ 1.35(t, 3H), 1.40(t, 3H), 4.19(s, 3H),  
4.27(g, 2H), 4.32(g, 2H), 6.95(dd, 1H),  
25 7.49(d, 1H), 7.94(d, 1H), 8.51(d, 1H)

(B) Ethyl 8-methoxy-1,7-naphthyridi-4(1H)-one-3-carboxylate  
28.5 g of ethyl 2-ethoxycarbonyl-3-(2-methoxypyridin-3-yl)aminoacrylate prepared in the above (A) was dissolved in 150 ml of diphenyl ether, and the resulting solution was 30 heated to reflux for 1.5 hours and cooled to about 60°C.

Petroleum ether was added to give precipitates, which were filtered to give 14.1g (59%) of the titled compound as brown crystals.

m.p. : 230 - 233°C

5  $^1\text{H-NMR}$  ( $\text{CDCl}_3/\text{DMSO-d}_6$ ) :  $\delta$  1.40(t, 3H), 4.18(s, 3H), 4.37(g, 2H), 7.69(d, 1H), 8.03(d, 1H), 8.51(s, 1H), 12.05(br.s, 1H)

(C) Ethyl 4-methanesulfonyl-8-methoxy-1,7-naphthyridin-3-carboxylate

10 4.96g of ethyl 2-methoxy-1,7-naphthyridi-4(1H)-one-3-carboxylate and 4.2 ml of triethylamine were dissolved into 70ml of dichloromethane, and a solution of methanesulfonyl chloride (1.85 ml) in dichloromethane (10 ml) was added dropwise at a temperature of 0°C to 5°C. The resulting 15 mixture was stirred for 1 hour at the same temperature. Water was added, and the resulting mixture was extracted with dichloromethane three times, and the organic phase was washed with water and then brine, dried over magnesium sulfate and distilled under reduced pressure. Ether was 20 added to the residue to give 4.4g (67%) of the titled compound as yellow crystals.

$^1\text{H-NMR}$  ( $\text{CDCl}_3$ ) :  $\delta$  1.48(t, 3H), 3.56(s, 3H), 4.25(s, 3H), 4.50(g, 2H), 7.71(d, 1H), 8.31(d, 1H), 9.40(s, 1H)

25 (D) Ethyl 4-(2-Methylphenylamino)-8-methoxy-1,7-naphthyridine-3-carboxylate

Ethyl 4-methanesulfonyl-8-methoxy-1,7-naphthyridine-3-carboxylate (261 mg and o-toluidine (0.17 ml) were dissolved into 7 ml of acetonitrile and the solution was 30 heated to reflux for 30 minutes. After cooling the mixture,

the solvent was evaporated under reduced pressure and the residue was dissolved into chloroform. The solution was washed with water and then saturated sodium bicarbonate, dried, and concentrated under reduced pressure. The 5 residue was subjected to silica gel column chromatography using a mixture of hexane : ethyl acetate (2:1) as an eluant to give yellow titled compound (180 mg, 67%).

m.p. 158°C

<sup>1</sup>H-NMR (CDCl<sub>3</sub>) : δ 1.47 (t, 3H), 2.39 (s, 3H), 4.19 (s, 3H),  
10 4.48 (g, 2H), 6.69 (d, 1H), 6.89-7.37 (m, 4H),  
7.68 (d, 1H), 9.29 (s, 1H), 10.47 (br.s, 1H)

#### Examples 2 - 17

By following the procedure described in Example 1 (D)  
15 by employing ethyl 4-methanesulfonyl-8-methoxy-1,7-naphthyridine -3-carboxylate prepared in Example 1 (C) and various amines under, there were obtained inventive compounds of Examples 2-17. These compounds and their physical properties are shown in Table 5.

20

#### Example 18

Preparation of 3-butyryl-4-(2-methylphenylamino)-8-methoxy-1,7-naphthyridine

(A) Ethyl 2-butyryl-3-(2-methoxypyridine-3-yl)aminoacrylate  
25 2-methoxy-3-aminopyridine (5.25g) and ethyl 2-butyryl-3-ethoxy acrylate (9.44g) were reacted at a temperature of 120°C to 130°C under heating for 30 minutes while distilling ethanol produced during the reaction. After completion of the reaction, the reaction mixture was 30 cooled to 60°C, and poured into petroleum ether (100 ml) and

cooled to 0°C. The resulting precipitates were filtered to give 11.24g (90%) of the titled compound.

<sup>1</sup>H-NMR (CDCl<sub>3</sub>) : δ 0.99(t, 3H), 1.38(t, 3H), 1.85(m, 2H),  
5 2.97(t, 2H), 4.12(s, 3H), 4.30(g, 2H),  
6.97(dd, 1H), 7.55(d, 1H), 7.99(d, 1H),  
8.51(d, 1H), 12.68(br.s, 1H)

(B) 3-Butyryl-8-methoxy-1,7-naphthyridi-4(1H)-one

11.23 g of ethyl 2-butyryl-3-(2-methoxypyridine-3-yl)aminoacrylate prepared in the above (A) was dissolved 10 in 60 ml of diphenyl ether, and the resulting solution was heated to reflux for 2 hours and cooled to about 50°C. Petroleum ether (200 ml) was added to give precipitates, which were filtered to give 6.3g (76%) of the titled compound as brown crystals.

15 m.p. : 206 - 207°C

<sup>1</sup>H-NMR (CDCl<sub>3</sub>/DMSO-d<sub>6</sub>) : δ 0.98(t, 3H), 1.69(m, 2H), 3.17(t, 2H), 4.15(s, 3H), 7.69(d, 1H), 8.04(d, 1H),  
8.45(s, 1H), 12.23(br.s, 1H)

(C) 3-Butyryl-4-methanesulfonyl-8-methoxy-1,7-naphthyridine

20 4.93g of 3-butyryl 8-methoxy-1,7-naphthyridi-4(1H)-one and 4.2 ml of triethylamine were dissolved into 70 ml of dichloromethane, and a solution of methanesulfonyl chloride (1.85 ml) in dichloromethane (10 ml) was added dropwise at a temperature of 0°C to 5°C. The resulting mixture was stirred 25 for 1 hour at the same temperature. Water was added, and the resulting mixture was extracted with dichloromethane three times, and the organic phase was washed with water and then brine, dried over magnesium sulfate and distilled under reduced pressure. Ether was added to the residue to give 30 4.61g (71%) of the titled compound as yellow crystals.

m.p. : 184-185°C

<sup>1</sup>H-NMR (CDCl<sub>3</sub>) : δ 1.05(t, 3H), 1.81(m, 2H), 3.05(t, 2H),  
3.49(s, 3H), 4.28(s, 2H), 7.67(s, 3H),  
8.25(d, 1H), 9.17(s, 1H)

5 (D) 3-Butyryl-4-(2-methylphenylamino)-8-methoxy-1,7-naphthyridine

3-Butyryl-4-methanesulfonyl-8-methoxy-1,7-naphthyridine (259 mg) and o-toluidine (0.17 ml) were dissolved into 7 ml of acetonitrile, and the solution was extracted with 10 chloroform, and the organic phase was washed with water and then saturated sodium bicarbonate. After drying, and concentration under reduced pressure, the resulting residue was subjected to silica gel column chromatography using a mixture of hexane : ethyl acetate (1:1) as an eluant to give 15 yellow titled compound (150 mg, 56%).

m.p. 144°C

<sup>1</sup>H-NMR (CDCl<sub>3</sub>) : δ 1.08(t, 3H), 1.85(m, 2H), 2.35(s, 3H),  
3.15(t, 2H), 4.19(s, 3H), 6.67(d, 1H),  
6.95-7.38(m, 4H), 7.65(d, 1H), 8.22(s, 1H),  
11.85(br.s, 1H)

20

#### Examples 19 - 32

By following the procedure described in Example 18 (D) by employing 3-butyryl-4-methanesulfonyl-8-methoxy-1,7-naphthyridine prepared in Example 18 (C) and various amines under, there were obtained inventive compounds of Examples 19-32. These compounds and their physical properties are shown in Table 5.

Example 33

preparation of 3-butyryl-8-ethoxy-4-(2-methylphenylamino)-1,7-naphthyridine

(A) 3-butyryl-8-ethoxy-4-(2-methylphenylamino)-1,7-

5 naphthyridine

Ethyl 2-butyryl-3-(2-ethoxypyridin-3-yl)aminoacrylate (93%) was prepared from 3-amino-2-ethoxypyridine and ethyl 2-butyryl-3-ethoxyacrylate by following the procedure similar to that of Example 18 (A), and then the product was subjected 10 to cyclization in a similar manner to that of Example 18 (B) to give 3-butyryl-8-ethoxy-1,7-naphthyridi-4(1H)-one (86%), which is then subjected to methanesulfonylation in a similar manner to that of Example 18 (C) to give 3-butyryl-8-methoxy-4-methanesulfonyl-1,7-naphthyridine (67%).

15 m.p. 115-116°C

<sup>1</sup>H-NMR (CDCl<sub>3</sub>) : δ 1.04(t, 3H), 1.50(t, 3H), 1.80(m, 2H), 3.00(t, 2H), 3.41(s, 3H), 4.32(s, 3H), 7.62(d, 1H), 8.23(d, 1H), 9.25(s, 1H)

(B) 3-Butyryl-8-ethoxy-4-(2-methylphenylamino)-1,7-naphthyridine

20 3-Butyryl-8-ethoxy-4-methanesulfonyl-1,7-naphthyridine (338 mg) and o-toluidine (214 mg) were dissolved into 7 ml of acetonitrile, and the solution was heated to reflux for 30 minutes and concentrated to evaporate solvent under reduced pressure. Water was added to the residue, and the mixture 25 was extracted with chloroform, and the organic phase was washed with water and then saturated sodium bicarbonate. After drying, and concentration under reduced pressure, the resulting residue was subjected to silica gel column chromatography using a mixture of hexane : ethyl acetate (2:1) 30 as an eluant to give yellow titled compound (300 mg, 86%).

m.p. 112°C

<sup>1</sup>H-NMR (CDCl<sub>3</sub>) : δ 1.05(t, 3H), 1.55(t, 3H), 1.83(m, 2H),  
2.36(s, 3H), 3.10(t, 2H), 4.61(g, 2H),  
6.65(d, 1H), 6.91-7.38(m, 4H), 7.82(d, 1H),  
9.25(d, 1H), 11.81(s, 1H)

5

Examples 34 - 42

By following the procedure described in Example 33 (B) by employing 3-butyryl-8-ethoxy-4-(2-methylphenylamino)-1,7-10 naphthyridine prepared in Example 33 (A) and various amines under, there were obtained inventive compounds of Examples 34-42. These compounds and their physical properties are shown in Table 5.

15 Example 43

Preparation of 3-Butyryl-8-isopropoxy-4-(2-methylphenylamino)-1,7-naphthyridine

(A) 3-Butyryl-8-isopropoxy-4-methanesulfonyl-1,7-naphthyridine

20 3-Amino-2-isopropoxypyridine was reacted in a similar manner to that of Example 33 (A) to give the titled compound.

<sup>1</sup>H-NMR (CDCl<sub>3</sub>) : δ 1.05(t, 3H), 1.51(d, 6H), 1.80(m, 2H),  
3.02(t, 2H), 3.45(s, 3H), 5.69(s, 3H),  
7.61(d, 1H), 8.23(d, 1H), 9.19(s, 1H)

25 (B) 3-Butyryl-8-isopropyl-4-(2-methylphenylamino)-1,7-naphthyridine

By following a similar procedure described in Example 33 (B) using 3-Butyryl-8-isopropyl-4-methanesulfonyl-1,7-naphthyridine (282 mg) and *o*-toluidine (0.17 ml) to give the 30 titled compound (168 mg, 58%).

<sup>1</sup>H-NMR (CDCl<sub>3</sub>) : δ 1.03(t, 3H), 1.52(d, 6H), 1.82(s, 3H), 2.38(s, 3H), 3.10(q, 2H), 5.59(m, 1H), 6.62(d, 1H), 6.90-7.35(m, 4H), 7.85(d, 1H), 9.30(s, 1H), 11.80(s, 1H)

5

Examples 44 - 45

By following the procedure described in Example 43 (B) by employing 3-butyryl-8-isopropoxy-4-methanesulfonyl-1,7-naphthyridine prepared in Example 43 (A) and various amines, 10 there were obtained inventive compounds of Examples 44-45. These compounds and their physical properties are shown in Table 5.

Example 46

15 Preparation of Ethyl -4-(2-methylphenylamino)-8-(4-morpholino)-1,7-naphthyridine-3-carboxylate

(A) Ethyl 4-methanesulfonyl-8-(4-morpholino)-1,7-naphthyridine-3-carboxylate

3-Amino-2-(4-morpholino)pyridine was reacted in 20 similar manners to those of Example 1 (A) - (C) to give the titled compound.

<sup>1</sup>H-NMR (CDCl<sub>3</sub>) : δ 1.45(t, 3H), 3.51(s, 3H), 3.80-4.05(m, 8H), 4.49(q, 2H), 7.50(d, 1H), 8.29(d, 1H), 9.27(s, 1H)

25 (B) Ethyl 4-(2-methylphenylamino)-8-(4-morpholino)-1,7-naphthyridine-3-carboxylate

By following a similar procedure described in Example 1 (D) using ethyl 4-methanesulfonyl-8-(4-morpholino)-1,7-naphthyridine-3-carboxylate (305 mg) and *o*-toluidine (0.17 30 ml) to give the titled compound (203 mg, 65%).

<sup>1</sup>H-NMR (CDCl<sub>3</sub>) : δ 1.46 (t, 3H), 2.40 (s, 3H), 3.75-4.01 (m, 8H), 4.45 (q, 2H), 6.65 (d, 1H), 6.80-7.35 (m, 4H), 7.75 (d, 1H), 9.19 (s, 1H)

5 Examples 47 - 57

By following the procedure described in Example 46 (B) by employing ethyl 4-methanesulfonyl-8-(4-morpholino)-1,7-naphthyridine-3-carboxylate prepared in Example 46 (A), there were obtained inventive compounds of Examples 47-57. 10 These compounds and their physical properties are shown in Table 5.

Example 58

Preparation of Ethyl 4-(2-methylphenylamino)-8-(1-piperidino)-1,7-naphthyridine-3-carboxylate

Ethyl 4-methanesulfonyl-8-(1-piperidino)-1,7-naphthyridine-3-carboxylate (303 mg) prepared by reacting 3-amino-2-(1-piperidino)pyridine in same manners as those of Example 1 (A) - (C) was reacted with *o*-toluidine (0.17 ml) in 20 the same manner as that of Example 1 (D) to give the titled compound (187 mg, 60%).

<sup>1</sup>H-NMR (CDCl<sub>3</sub>) : δ 1.25 (t, 3H), 1.60-1.90 (m, 6H), 2.25 (s, 3H), 3.81 (m, 4H), 4.45 (q, 2H), 6.59 (d, 1H), 6.80-7.38 (m, 4H), 7.78 (d, 1H), 9.20 (s, 1H), 25 10.25 (br.s, 1H)

Example 59

Preparation of Ethyl 4-(1-indanylamino)-8-(1-piperidino)-1,7-naphthyridine-3-carboxylate

30 Ethyl 4-methanesulfonyl-8-(1-piperidino)-1,7-

naphthyridine-3-carboxylate (303 mg) prepared in Example 58 was reacted with 1-aminoindane in the same manner as that of Example 58 to give the titled compound (60%).

<sup>1</sup>H-NMR (CDCl<sub>3</sub>) : δ 1.39 (t, 3H), 1.62-1.88 (m, 6H),  
5 2.00-2.23 (m, 1H), 2.65-3.15 (m, 3H), 3.80 (m, 4H), 4.45 (q, 2H), 5.64 (q, 1H), 7.20-7.50 (m, 5H), 8.04 (d, 1H), 9.05 (d, 1H), 9.08 (s, 1H)

10

15

20

25

30

Table 5

Compound	R <sub>1</sub>	R <sub>2</sub>	Ar	Yield(%) m.p.(°C)	<sup>1</sup> H-NMR(CDCl <sub>3</sub> )
Example 2	Ethoxy	Methoxy	Phenyl	62	127 1.45(t,3H), 4.20(s,3H), 4.48(q,2H), 6.85(d,1H), 7.05-7.40(m,5H), 7.75(d,1H), 9.30(s,1H), 10.50(br,s,1H).
Example 3	Ethoxy	Methoxy	2-Methoxyphenyl	67	194 1.45(t,3H), 3.84(s,3H), 4.21(s,3H), 4.48(q,2H), 6.80-7.25(m,5H), 6.78(d,1H), 9.29(s,1H), 10.30(s,1H).
Example 4	Ethoxy	Methoxy	2-Trifluoromethylphenyl	35	146 1.44(t,3H), 4.20(s,3H), 4.50(q,2H), 6.70(d,1H), 6.82(d,1H), 7.35(m,3H), 7.79(d,1H), 9.39(s,1H), 10.55(s,1H).
Example 5	Ethoxy	Methoxy	2-Chlorophenyl	58	160 1.45(t,3H), 4.21(s,3H), 4.49(q,2H), 6.82(d,1H), 6.83(m,1H), 7.15(m,2H), 7.53(m,1H), 7.80(d,1H), 9.38(s,1H), 10.39(s,1H).
Example 6	Ethoxy	Methoxy	2-Fluorophenyl	60	146 1.49(t,3H), 4.22(s,3H), 4.50(q,2H), 6.88(d,1H), 7.00-7.25(m,4H), 7.79(d,1H), 9.33(s,1H), 10.30(s,1H).
Example 7	Ethoxy	Methoxy	4-Methylphenyl	61	151 1.45(t,3H), 2.39(s,3H), 4.20(s,3H), 4.47(q,2H), 6.85(d,1H), 6.99(d,2H), 7.18(d,2H), 7.72(d,1H), 9.28(s,1H), 10.49(s,1H).
Example 8	Ethoxy	Methoxy	3-Methoxyphenyl	64	174 1.47(t,3H), 3.78(s,3H), 4.20(s,3H), 4.49(q,2H), 6.60-6.81(m,3H), 6.95(d,1H), 7.21(d,1H), 7.79(d,1H), 9.20(s,1H), 10.45(s,1H).
Example 9	Ethoxy	Methoxy	4-Methoxyphenyl	60	139 1.46(t,3H), 3.85(s,3H), 4.19(s,3H), 4.45(q,2H), 6.81(d,1H), 6.90(d,2H), 7.05(d,2H), 7.70(d,1H), 9.25(s,1H), 10.55(s,1H).

Example 10	Ethoxy	Methoxy	3-Fluorophenyl	57	152	1.49(t,3H), 7.81(d,1H), 9.35(s,1H), 10.40(s,1H),	4.22(s,3H), 4.50(q,2H), 6.72-6.98(m,3H), 7.30(m,1H),
Example 11	Ethoxy	Methoxy	4-Fluorophenyl	59	161	1.47(t,3H), 9.30(s,1H), 10.45(s,1H),	4.19(s,3H), 4.48(q,2H), 6.79(d,1H), 7.05(d,4H), 7.75(d,1H),
Example 12	Ethoxy	Methoxy	4-n-Butoxyphenyl	44	105	1.00(t,3H), 4.45(q,2H), 6.81(d,1H), 10.55(s,1H),	1.50(t,3H), 6.85(d,2H), 7.05(d,2H), 7.71(d,1H), 9.25(s,1H),
Example 13	Ethoxy	Methoxy	4-n-Butylphenyl	37	108	0.97(t,3H), 6.85(d,1H), 7.00(d,2H), 7.17(d,2H), 7.71(d,1H),	1.25-1.70(m,4H), 1.45(t,3H), 2.63(t,2H), 4.20(s,3H), 4.47(q,2H), 5.27(s,1H), 10.48(s,1H).
Example 14	Ethoxy	Methoxy	(R)-1-Phenylethyl	69	109	1.45(t,3H), 7.80(d,1H), 9.18(s,1H), 9.55(d,1H),	1.69(d,3H), 4.15(s,1H), 4.44(q,2H), 5.30(m,1H), 7.35(m,6H),
Example 15	Ethoxy	Methoxy	(S)-1-Phenylethyl	60	110	1.45(t,3H), 7.80(d,1H), 9.19(s,1H), 9.55(d,1H),	1.69(d,3H), 4.14(s,1H), 4.45(q,2H), 5.30(m,1H), 7.35(m,6H),
Example 16	Ethoxy	Methoxy	Benzyl	85	148	1.42(t,3H), 7.91(d,1H), 9.19(s,1H), 9.55(br,s,1H)	4.20(s,3H), 4.40(q,2H), 5.00(d,2H), 7.40(m,5H), 7.55(d,1H),
Example 17	Ethoxy	Methoxy	2-Methylthiophenyl	71	174	1.45(t,3H), 7.75(d,1H), 9.30(s,1H), 10.40(s,1H),	2.53(s,3H), 4.20(s,3H), 4.45(q,2H), 6.76(d,1H), 6.77-7.40(m,4H),
Example 19	n-Propyl	Methoxy	4-Methylphenyl	62	145	1.05(t,3H), 7.01(d,2H), 7.18(d,2H), 7.70(d,1H), 9.21(s,1H), 11.82(s,1H)	1.82(m,2H), 2.39(s,3H), 3.13(t,2H), 4.19(s,3H), 6.83(d,1H),
Example 20	n-Propyl	Methoxy	Phenyl	64	119	1.05(t,3H), 7.09-7.40(m,5H), 7.71(d,1H), 9.22(s,1H), 11.81(s,1H),	1.781(m,2H), 3.12(t,2H), 4.20(s,3H), 6.82(d,1H),
Example 21	n-Propyl	Methoxy	(R)-1-Phenylethyl	57	111	1.07(t,3H), 7.25-7.49(m,6H), 7.80(d,1H), 9.15(s,1H), 11.31(d,1H),	1.73(d,3H), 1.82(m,2H), 3.08(t,2H), 4.18(s,3H), 5.37(m,1H),

Example 22 n-Propyl	Methoxy	(S)-1-Phenylethyl	54	110	1.05(t,3H), 1.73(d,3H), 1.81(m,2H), 3.08(t,2H), 4.18(s,3H), 5.38(m,1H), 7.24-7.46(m,6H), 7.79(d,1H), 9.13(s,1H), 11.13(d,1H).
Example 23 n-Propyl	Methoxy	2-Methoxyphenyl	63	135	1.03(t,3H), 1.81(m,2H), 3.12(t,2H), 3.70(s,3H), 4.20(s,3H), 6.83-7.27(m,5H), 7.70(d,1H), 9.21(s,1H), 11.67(s,1H).
Example 24 n-Propyl	Methoxy	3-Methoxyphenyl	60	144	1.07(t,3H), 1.83(m,2H), 3.18(t,2H), 3.80(s,3H), 4.20(s,3H), 6.65-6.85(m,4H), 6.95(d,1H), 7.30(d,1H), 7.78(d,1H), 9.25(s,1H), 11.80(s,1H).
Example 25 n-Propyl	Methoxy	4-Methoxyphenyl	50	125	1.05(t,3H), 1.82(m,2H), 3.16(t,2H), 3.82(s,3H), 4.19(s,3H), 6.80(s,1H), 6.91(d,2H), 7.08(d,2H), 7.69(d,1H), 9.20(s,1H), 11.90(s,1H).
Example 26 n-Propyl	Methoxy	2-Methylthiophenyl	73	107	1.08(t,3H), 1.85(m,2H), 2.52(s,3H), 3.15(t,2H), 4.20(s,3H), 6.75(s,1H), 6.88-7.40(m,4H), 7.71(d,1H), 9.24(s,1H), 11.76(s,1H).
Example 27 n-Propyl	Methoxy	Benzyl	75	129	1.01(t,3H), 1.79(m,2H), 3.01(t,2H), 4.19(s,3H), 5.00(d,2H), 7.40(m,5H), 7.55(d,1H), 7.90(d,1H), 9.12(s,1H), 11.05(br,s,1H).
Example 28 n-Propyl	Methoxy	2-Phenylethyl	64	98	1.03(t,3H), 1.79(m,2H), 3.05(m,4H), 4.12(m,2H), 4.20(s,3H), 7.30(m,5H), 7.60(d,1H), 7.97(d,1H), 9.05(s,1H), 10.85(s,1H).
Example 29 n-Propyl	Methoxy	4-Phenyl- <i>n</i> -butyl	50	90	1.05(t,3H), 1.80-2.05(m,6H), 2.71(m,2H), 3.03(t,2H), 3.85(m,2H), 4.21(s,1H), 7.28(m,5H), 7.60(d,1H), 7.98(d,1H), 9.05(s,1H), 10.82(s,1H).
Example 30 n-Propyl	Methoxy	4- <i>n</i> -Butylphenyl	66	94	0.91(t,3H), 1.04(t,3H), 1.21-1.90(m,6H), 2.62(t,2H), 3.07(t,2H), 4.18(s,3H), 6.81(d,1H), 7.02(d,2H), 7.18(d,2H), 7.65(d,1H), 8.22(s,1H), 11.80(s,1H).
Example 31 n-Propyl	Methoxy	3-Indanyl	34	156	1.05(t,3H), 1.81(m,2H), 2.15(m,2H), 2.90(m,4H), 3.12(t,2H), 4.20(s,3H), 6.85-7.03(m,3H), 7.20(d,1H), 7.70(d,1H), 9.20(s,1H), 11.86(s,1H).
Example 32 n-Propyl	Methoxy	1,2,3,4-Tetrahydro-1-naphthyl	31	119	1.02(t,3H), 1.60-2.30(m,6H), 2.87(m,2H), 3.00(t,2H), 4.20(s,3H), 5.40(m,1H), 7.10-7.35(m,4H), 7.59(d,1H), 7.99(d,1H), 9.15(s,1H), 10.75(d,1H).

Example 34 n-Propyl	Ethoxy	2-Methylthiophenyl	79	136	1.05(t,3H), 1.58(t,3H), 1.85(m,2H), 2.52(s,3H), 3.11(t,2H), 4.62(q,2H),
Example 35 n-Propyl	Ethoxy	4-n-Butylphenyl	86	121	0.96(t,3H), 1.03(t,3H), 1.25-1.90(m,6H), 1.50(t,3H), 2.61(t,2H), 3.17(t,2H), 6.70(d,1H), 6.85-7.38(m,4H), 7.69(d,1H), 9.25(s,1H), 11.70(s,1H).
Example 36 n-Propyl	Ethoxy	(S)-1-Phenylethyl	69	75	4.61(q,2H), 6.80(q,1H), 7.01(t,2H), 7.18(d,2H), 7.65(d,1H), 9.21(s,1H), 11.80(s,1H).
Example 37 n-Propyl	Ethoxy	(R)-1-Phenylethyl	69	76	1.03(t,3H), 1.56(t,3H), 1.70(d,3H), 1.70(d,3H), 1.82(m,2H), 3.05(t,2H), 4.60(q,2H), 5.35(m,1H), 7.21-7.50(m,6H), 7.79(d,1H), 9.17(s,1H), 11.07(d,1H).
Example 38 n-Propyl	Ethoxy	4-Methylphenyl	86	137	1.03(t,3H), 1.57(t,3H), 1.69(d,3H), 1.81(m,2H), 3.05(t,2H), 4.60(q,2H), 5.36(m,1H), 7.20-7.50(m,6H), 7.78(d,1H), 9.17(s,1H), 10.05(d,1H).
Example 39 n-Propyl	Ethoxy	4-Fluorophenyl	74	157	1.05(t,3H), 1.58(t,3H), 1.83(m,2H), 2.39(s,1H), 3.16(t,2H), 4.62(q,2H), 6.82(d,1H), 6.96-7.23(q,4H), 7.70(d,1H), 9.25(s,1H), 11.82(s,1H), 7.10(m,4H), 7.70(d,1H), 9.28(s,1H), 11.79(s,1H).
Example 40 n-Propyl	Ethoxy	2-Trifluoromethyl-phenyl	57	160	1.06(t,3H), 1.60(t,3H), 1.89(m,2H), 3.14(t,2H), 4.68(q,2H), 6.67(d,1H), 6.90(d,1H), 7.38(m,2H), 7.73(d,1H), 7.78(d,1H), 9.32(s,1H), 11.81(s,1H).
Example 41 n-Propyl	Ethoxy	4-Phenyl-n-butyl	57	73	1.01(t,3H), 1.58(t,3H), 1.58-1.90(m,6H), 2.67(m,2H), 3.00(t,2H), 4.67(q,2H), 3.81(m,2H), 4.62(q,2H), 7.12-7.37(m,5H), 7.58(d,1H), 7.95(d,1H), 9.08(s,1H), 10.80(s,1H).
Example 42 n-Propyl	Ethoxy	1,2,3,4-Tetrahydro-1-naphthyl	59	136	1.02(t,3H), 1.61(t,3H), 1.68-2.30(m,6H), 2.90(m,2H), 3.00(t,2H), 4.67(q,2H), 5.42(m,1H), 7.12-7.35(m,4H), 7.60(d,1H), 7.98(d,1H), 9.18(s,1H), 10.70(d,1H).
Example 44 n-Propyl	i-Propoxy	2-Methylthiophenyl	70	144	1.05(t,3H), 1.52(d,6H), 1.85(m,2H), 2.51(s,3H), 3.10(t,2H), 4.67(q,2H), 6.68(d,1H), 6.82-7.40(m,4H), 7.69(d,1H), 9.30(s,1H), 10.65(s,1H).
Example 45 n-Propyl	i-Propoxy	2-Trifluoromethyl-phenyl	36	127	1.04(t,3H), 1.53(d,6H), 1.84(m,2H), 3.12(t,2H), 5.61(m,1H), 6.63(d,1H), 6.92(d,1H), 7.39(m,2H), 7.73(d,1H), 7.79(d,1H), 9.37(s,1H), 11.80(d,1H).

Example 47 Ethoxy	4-Morpholino[	Phenyl	73	1.45(t,1H), 3.95(m,8H), 4.45(q,2H), 6.80(d,1H), 7.00-7.58(m,5H), 7.80(d,1H), 9.18(s,1H), 10.40(s,1H).
Example 48 Ethoxy	4-Morpholino[	4-Methyl[phenyl	68	1.44(t,3H), 2.38(s,3H), 3.90(m,8H), 4.45(q,2H), 6.96(d,2H), 7.15(d,2H), 7.79(d,1H), 9.19(s,1H), 10.38(s,1H).
Example 49 Ethoxy	4-Morpholino[	2-Methoxyphenyl	77	1.43(t,3H), 3.70-4.20(m,11H), 4.42(q,2H), 6.75-7.22(m,5H), 7.81(d,1H), 9.19(s,1H), 10.21(s,1H).
Example 50 Ethoxy	4-Morpholino[	3-Methoxyphenyl	72	1.45(t,3H), 3.78(s,3H), 3.92(m,8H), 4.45(q,2H), 6.60-7.30(m,5H), 7.82(d,1H), 9.20(s,1H), 10.34(s,1H).
Example 51 Ethoxy	4-Morpholino[	4-Methoxyphenyl	69	1.42(t,3H), 3.75-4.03(m,11H), 4.42(q,2H), 6.71-7.10(m,5H), 7.78(d,1H), 9.17(s,1H), 10.42(s,1H).
Example 52 Ethoxy	4-Morpholino[	2-Methylthiophenyl	70	1.46(t,4,3H), 2.55(s,3H), 3.91(m,8H), 4.46(q,2H), 6.67-7.40(m,5H), 7.80(d,1H), 9.20(s,1H).
Example 53 Ethoxy	4-Morpholino[	3-Methylthiophenyl	63	1.47(t,3H), 2.45(s,3H), 3.95(m,8H), 4.45(q,2H), 6.72-7.29(m,5H), 7.83(d,1H), 9.20(s,1H), 10.18(s,1H).
Example 54 Ethoxy	4-Morpholino[	2-Fluorophenyl	72	1.47(t,3H), 3.96(m,8H), 4.45(q,2H), 6.80(d,1H), 6.90-7.20(m,4H), 7.82(d,1H), 9.20(s,1H), 10.22(s,1H).
Example 55 Ethoxy	4-Morpholino[	3-Trifluoromethyl- phenyl	70	1.44(t,3H), 3.97(br,s,8H), 4.45(q,2H), 6.71(d,1H), 7.10-7.47(m,4H), 7.85(d,1H), 9.21(s,1H), 10.39(s,1H).
Example 56 Ethoxy	4-Morpholino[	4-n-Butoxyphenyl	67	1.00(t,3), 1.47(t,3H), 1.42-1.85(m,4H), 3.80-4.15(m,8H), 4.44(q,2H), 6.72-7.10(m,5H), 7.79(d,1H), 9.18(s,1H), 10.40(s,1H).
Example 57 Ethoxy	4-Morpholino[	1-Indanyl	65	1.42(t,3H), 2.15(m,1H), 2.69-3.15(m,3H), 3.80-4.15(m,8H), 4.46(q,2H), 5.65(q,1H), 7.20-7.45(m,4H), 7.57(d,1H), 8.05(d,1H), 9.10(s,1H), 9.15(d,1H).

It is understood that the foregoing detailed description is given merely by way of illustration and that modifications and variations may be made therein without departing from the spirit and scope of the invention.

5

10

15

20

25


30

## CLAIMS

1. A compound represented by the following general formula  
(I) :

5

10



wherein

R<sub>1</sub> is hydrogen atom, a C<sub>1</sub> - C<sub>6</sub> lower alkyl group, a C<sub>1</sub> - C<sub>6</sub> lower alkoxy group, C<sub>1</sub> - C<sub>6</sub> lower alkoxyalkyl group, a C<sub>3</sub> - C<sub>6</sub> cycloalkyl group, a C<sub>3</sub> - C<sub>6</sub> cycloalkyl C<sub>1</sub> - C<sub>6</sub> alkyl group, a substituted or unsubstituted phenyl, or a phenyl C<sub>1</sub> - C<sub>6</sub> alkyl group of which phenyl group may be substituted;

R<sub>2</sub> is hydrogen atom, a C<sub>1</sub> - C<sub>6</sub> lower alkyl group, a C<sub>1</sub> - C<sub>6</sub> alkoxy group, a C<sub>1</sub> - C<sub>6</sub> alkylthio group, or a group of a formula : NR<sub>6</sub>R<sub>7</sub> wherein R<sub>6</sub> and R<sub>7</sub>, identical to or different from each other, are independently hydrogen atom or a C<sub>1</sub> - C<sub>6</sub> lower alkyl group, or R<sub>6</sub> and R<sub>7</sub> may form together 5-membered or 6-membered cycloalkyl group;

R<sub>3</sub> is hydrogen atom, a C<sub>1</sub> - C<sub>6</sub> lower alkyl group, a C<sub>1</sub> - C<sub>6</sub> alkoxy group, a C<sub>1</sub> - C<sub>6</sub> alkylthio group, an amino group substituted with one or two C<sub>1</sub> - C<sub>6</sub> alkyl groups, a halogen atom, a cyano group, a C<sub>1</sub> - C<sub>6</sub> alkanoyl group, or trifluoromethyl group;

R<sub>4</sub> is hydrogen atom or a substituted or unsubstituted C<sub>1</sub> - C<sub>6</sub> alkyl group;

R<sub>5</sub> is hydrogen atom, a C<sub>1</sub> - C<sub>6</sub> lower alkyl group, a C<sub>1</sub> - C<sub>6</sub> alkoxy group, an amino group substituted with one or two C<sub>1</sub> - C<sub>6</sub> alkyl groups, a C<sub>1</sub> - C<sub>6</sub> alkylthio group, a halogen atom, a cyano group, a hydroxycarbamoyl group, a carboxy group, a C<sub>1</sub> - C<sub>6</sub> alkanoyl group, or trifluoromethyl group, or an alkyl group which forms together with R<sub>4</sub> a 5-membered or 6-membered cycloalkyl group;

5 m is an integer from 0 to 4, inclusive; and

n is an integer from 1 to 3, inclusive;

10 with proviso that all alkyl and alkoxy groups may be linear or branched, and said halogen atom means fluorine, chlorine or bromine atom,

or its pharmaceutically acceptable salts.

15 2. The compound (I) according to claim 1, wherein R<sub>1</sub> is ethoxy or propyl group; R<sub>5</sub> is methoxy, ethoxy, propyl, isopropyl, hydroxyethoxy, piperidino or morpholino group; R<sub>3</sub> is hydrogen atom; R<sub>4</sub> is hydrogen atom, or methyl or ethyl group; R<sub>5</sub> is hydrogen atom, or methyl, ethyl, vinyl.

20 trifluoromethyl, methoxy, or ethoxy group, or chlorine or fluorine atom, or an allyl or butyl group, or an alkyl group forming together with R<sub>4</sub> a 5-membered or 6-membered cycloalkyl group; m is an integer of 0 to 4; and n is an integer of 1 or 2, or its pharmaceutically acceptable salts.

25

3. The compound (I) according to claim 2, wherein R<sub>1</sub> is ethoxy or propyl group; R<sub>5</sub> is methoxy, ethoxy, or isopropyl group; R<sub>3</sub> is hydrogen atom; R<sub>4</sub> is methyl or ethyl group; R<sub>5</sub> is hydrogen atom; m is an integer of 1; and n is an integer of 30 1, or its pharmaceutically acceptable salts.

4. The compound (I) according to claim 2, wherein  $R_1$  is ethoxy or propyl group;  $R_5$  is methoxy, ethoxy, isopropyl, hydroxyethoxy, piperidino or morpholino group;  $R_3$  is hydrogen atom;  $R_5$  is hydrogen atom, or methyl, ethyl, vinyl, trifluoromethyl, methoxy, or ethoxy group, or chlorine or fluorine atom, or an allyl or butyl group, or an alkyl group forming together with  $R_4$  a 5-membered or 6-membered cycloalkyl group;  $m$  is cypher; and  $n$  is an integer of 1 or 2, or its pharmaceutically acceptable salts.


10

5. The compound (I) according to claim 1, which is 3-Butyryl-4-(1,2,3,4-tetrahydro-1-naphthylamino)-8-methoxy-1,7-naphthyridine, or its pharmaceutically acceptable salts.

15 6. The compound (I) according to claim 1, which is 3-Butyryl-4-(5-(R)-(+)-methylbenzylamino)-8-ethoxy-1,7-naphthyridine, or its pharmaceutically acceptable salts.

7. A process for producing a compound represented by the  
20 following general formula (I):

25



wherein

30  $R_1$  is hydrogen atom, a  $C_1 - C_6$  lower alkyl group, a  $C_1 - C_6$

lower alkoxy group, C<sub>1</sub> - C<sub>6</sub> lower alkoxyalkyl group, a C<sub>3</sub> - C<sub>6</sub> cycloalkyl group, a C<sub>3</sub> - C<sub>6</sub> cycloalkyl C<sub>1</sub> - C<sub>6</sub> alkyl group, a substituted or unsubstituted phenyl, or a phenyl C<sub>1</sub> - C<sub>6</sub> alkyl group of which phenyl group may be 5 substituted;

R<sub>2</sub> is hydrogen atom, a C<sub>1</sub> - C<sub>6</sub> lower alkyl group, a C<sub>1</sub> - C<sub>6</sub> alkoxy group, a C<sub>1</sub> - C<sub>6</sub> alkylthio group, or a group of a formula : NR<sub>6</sub>R<sub>7</sub> wherein R<sub>6</sub> and R<sub>7</sub>, identical to or different from each other, are independently hydrogen 10 atom or a C<sub>1</sub> - C<sub>6</sub> lower alkyl group, or R<sub>6</sub> and R<sub>7</sub> may form together 5-membered or 6-membered cycloalkyl group;

R<sub>3</sub> is hydrogen atom, a C<sub>1</sub> - C<sub>6</sub> lower alkyl group, a C<sub>1</sub> - C<sub>6</sub> alkoxy group, a C<sub>1</sub> - C<sub>6</sub> alkylthio group, an amino group substituted with one or two C<sub>1</sub> - C<sub>6</sub> alkyl groups, a 15 halogen atom, a cyano group, a C<sub>1</sub> - C<sub>6</sub> alkanoyl group, or trifluoromethyl group;

R<sub>4</sub> is hydrogen atom or a substituted or unsubstituted C<sub>1</sub> - C<sub>6</sub> alkyl group;

R<sub>5</sub> is hydrogen atom, a C<sub>1</sub> - C<sub>6</sub> lower alkyl group, a C<sub>1</sub> - C<sub>6</sub> 20 alkoxy group, an amino group substituted with one or two C<sub>1</sub> - C<sub>6</sub> alkyl groups, a C<sub>1</sub> - C<sub>6</sub> alkylthio group, a halogen atom, a cyano group, a hydroxycarbamoyl group, a carboxy group, a C<sub>1</sub> - C<sub>6</sub> alkanoyl group, or trifluoromethyl 25 group, or an alkyl group which forms together with R<sub>4</sub> a 5-membered or 6-membered cycloalkyl group;


m is an integer from 0 to 4, inclusive; and

n is an integer from 1 to 3, inclusive;

with proviso that all alkyl and alkoxy groups may be linear or branched, and said halogen atom means fluorine, 30 chlorine or bromine atom,

or its pharmaceutically acceptable salts,  
 which comprises a step of reacting a compound represented by  
 a general formula (II):

5




10

wherein, R<sub>1</sub>, R<sub>2</sub>, and R<sub>3</sub> have the same meanings as defined above; and X is chlorine atom, OS(O)<sub>2</sub>R<sub>8</sub> or OP(O)(OR<sub>9</sub>)<sub>2</sub> in which R<sub>8</sub> is methyl, ethyl, trifluoromethyl, phenyl, or 15 p-toluenyl group, and R<sub>9</sub> is methyl, ethyl, propyl, or phenyl group which may be substituted,


or its pharmaceutically acceptable salts  
 with a compound represented by a general formula (III)

20



25 wherein R<sub>4</sub>, R<sub>5</sub>, m and n have the same meaning as defined above.


8. The process according to claim 7, wherein the compound (II) or its pharmaceutically acceptable salts are prepared 30 by reacting a compound represented by a general formula (IV):



(IV)

5

wherein, R<sub>2</sub> and R<sub>3</sub> have the same meanings as defined in claim 7, with a compound represented by a general formula (V) :




(V)

10

wherein, R<sub>1</sub> has the same meaning as defined in claim 7, to give a compound represented by a general formula (VI) :


15



20

wherein, R<sub>1</sub>, R<sub>2</sub>, and R<sub>3</sub> have the same meanings as defined in claim 7;

subjecting the compound (VI) to a cyclization to give a 25 compound represented by a general formula (VII) :



(VII)

30

wherein,  $R_1$ ,  $R_2$ , and  $R_3$  have the same meanings as defined in claim 7;

subjecting the compound (VII) to a halogenation, sulfonation  
5 or phosphonation to give the compound (II).

10

15

20

25

30

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/KR 96/00080

## A. CLASSIFICATION OF SUBJECT MATTER

IPC<sup>6</sup>: C 07 D 471/04

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC<sup>6</sup>: C 07 D 471/00

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

AT, Chem. Abstr.

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Questel: DARC, WPIL

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 346 208 A1 (SANOFI) 13 December 1989 (13.12.89), claims 1,21.	1-8
A	EP 0 346 207 A1 (SANOFI) 13 December 1989 (13.12.89), claims 1,4.	1-8
A	EP 0 115 469 A1 (CIBA GEIGY) 08 August 1984 (08.08.84), examples 8,11a-11g.	1-8
A	Chemical Abstracts, Vol.69, No.5, 29 July 1968 (Columbus, Ohio, USA), page 1793, column 2, abstract No.19051p, CHIEN, Ping-Lu et al.: "Synthesis and antimalarial evaluation of some 1,7-naphthyridines and 2,9-diazaanthracenes", J.Med.Chem. 1968, 11(1), 164-7 (Eng).	1-8
A	EP 0 339 769 A1 (SMITHKLINE BECKMAN INTERCREDIT B.V.) 02 November 1989 (02.11.89), claims 1,7 (cited in the application).	1-8
	-----	

<input type="checkbox"/>	Further documents are listed in the continuation of Box C.	<input checked="" type="checkbox"/> See patent family annex.
--------------------------	--	--

• Special categories of cited documents:	
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier document but published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
07 August 1996 (07.08.96)	27 August 1996 (27.08.96)
Name and mailing address of the ISA/AT AUSTRIAN PATENT OFFICE Kohlmarkt 8-10 A-1014 Vienna Facsimile No. 1/53424/535	Authorized officer Hammer Telephone No. 1/5337058/44

4-Substituted amino-quinoline or 1,7-naphthyridine-3-carboxylic acid derivatives in racemic or enantiomeric form, and their pharmaceutically acceptable acid or base addition salts are claimed in the EP-346208. These compounds bind to peripheral, but not central, benzodiazepine receptors. They are peripheral vasodilators for increasing coronary blood flow; immunomodulators and anxiety modifiers and are useful e.g. for preventing or treating cardiovascular diseases; as antiallergic agents, and for treatment of infections and anxiety conditions.

In the EP-346207 4-amino-3-carboxy 1,7-naphthyridine derivatives their N-oxides on heterocyclic nitrogen, and addn. salts with pharmaceutically-acceptable acids and bases, are described. These 4-amino-3-carboxy-naphthyridines have anxiolytic, anticonvulsant, sedative and hypnotic activity.

2-Substituted tricyclic pyrazolo-pyridinone derivatives are claimed in the EP-115459, which are modulators of benzodiazepine receptors, so have anxiolytic and anticonvulsant activities and antagonise the effects of benzodiazepine drugs and have also adenosine-antagonising activity. As preproducts 1,7-naphthyridines e.g. 4-methoxyamino- N-phenyl-1,7-naphthyridine-3-carboxamide or -3-bromo are mentioned.

Chemical Abstracts 69:19051p describes the synthesis of some 1,7-naphthyridines e.g. Phenol, 2-[(diethylamino)methyl]-4-(1,7-naphthyridin-4-ylamino)-, 1,3-Propanediamine, N,N-diethyl-N'-1,7-naphthyridin-4-yl- and 1,4-Pentanediamine, N1,N1-diethyl-N4-1,7-naphthyridin-4-yl-, which have antimalarial activity.

New 4-amino-3-acyl quinolin derivatives are claimed in the EP-339768. These compounds inhibit exogenously and endogenously stimulated gastric acid secretion and are useful in the treatment of gastrointestinal diseases including gastric and duodenal ulcers, aspiration pneumonitis and Zollinger-Ellison Syndrome and can also be used in the treatment of other disorders where an anti-secretory effect is desirable, e.g. in patients with gastritis, NSAID induced gastritis, acute upper intestinal bleeding, in patients with a history of chronic and excessive alcohol consumption, and in patients with gastro-oesophageal reflux disease.

**INTERNATIONAL SEARCH REPORT**  
Information on patent family members

International application No.

PCT/KR 96/00080

Im Recherchenbericht angeführtes Patentdokument Patent document cited in search report Document de brevet cité dans le rapport de recherche	Datum der Veröffentlichung Publication date Date de publication	Mitglied(er) der Patentfamilie Patent family member(s) Membre(s) de la famille de brevets	Datum der Veröffentlichung Publication date Date de publication
EP A1 346208	13-12-89	AT E 104288 AU A1 360257/89 AU B2 624825 CA A1 173707/89 DE CO 6891451/90 DE T2 6891451/90 DK A0 2736/89-90 DK A 2736/89-90 EP B1 346208/90 EP T2 206315/90 FR A1 2632861 FR B1 2632861 JP A2 2072059 NZ A 229413/90 PT A 907408/90 PT B 907408/90 FR A1 2632230/90 FR B1 2632230/90 UG A 890421-91 ZA A 8904250	15-04-94 02-12-89 25-06-92 19-08-92 19-05-94 19-08-94 02-06-89 02-12-89 19-04-94 01-01-95 02-12-89 09-11-90 19-04-95 01-02-90 27-11-90 28-11-90 01-10-94 15-05-92 15-06-91 27-02-91
EP A1 346207	13-12-89	AT E 102199 DE CO 68913365 DE TN 68913365 EP B1 346207/90 FR A1 2632639 FR B1 2632639 JP A2 20032078 US A 4996213	15-03-94 07-04-94 11-08-94 02-03-94 15-12-89 05-10-90 01-02-90 26-02-91
EP A1 115469	08-08-84	AT E 27276 AU A1 23171/84 CA A1 1250579 DD A5 216019 DE CO 3463769 DE A0 80/84 DK A0 80/84 EP B1 115469 EP A1 2628750 EP A5 529750 EP A1 B606342 EP A1 544184 FI A0 8400574 FI A 8400574 GR A 794566 IL A0 706355 JP A2 59130888 NO A 840068 PT A 77926 PT B 77926 US A 447995 ZA A 8400154 US A 4560689	15-06-87 12-07-84 28-02-89 29-11-84 20-06-87 09-01-84 11-07-84 20-05-87 01-04-86 30-04-86 01-10-86 01-12-86 06-01-84 11-07-84 15-10-84 20-04-84 27-07-84 11-07-84 02-06-84 20-10-84 29-08-84 24-12-85
EP A1 339769	02-11-89	US A 4895706 JP A2 2149321 US A 4948564 US A 5084246 US A 5110556	23-01-90 07-05-90 14-08-90 28-01-92 05-05-92